CN1194831A - Ribavirin large infusion series preparation - Google Patents
Ribavirin large infusion series preparation Download PDFInfo
- Publication number
- CN1194831A CN1194831A CN97102748A CN97102748A CN1194831A CN 1194831 A CN1194831 A CN 1194831A CN 97102748 A CN97102748 A CN 97102748A CN 97102748 A CN97102748 A CN 97102748A CN 1194831 A CN1194831 A CN 1194831A
- Authority
- CN
- China
- Prior art keywords
- ribavirin
- large infusion
- injection
- sodium chloride
- series preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A series of Ribavirin medicines for infusion contains sodium chloride (0.6-0.9g), glucose (5-10g) and Ribavirin (0.5-1g) in each 100 ml of such medicine, and features large dosage of Libaweilin, convenient application, no cross infection and high safety.
Description
Ribavirin claims ribavirin, virazole again, is broad-spectrum antiviral drug commonly used clinically both at home and abroad.The ribavirin antiviral spectrum is wide, to influenza virus A, B-mode, parainfluenza virus I, II, III type, the viruses of kind more than 30 such as Respirovirus, Measles virus, mumps virus all have activity, its mechanism of action mainly is suppress viral nucleic acid synthetic, disturbs DNA synthetic, thereby stops virus replication.The i.e. synthetic as far back as 1970 and since have antitoxin activity strong, be difficult for producing drug resistance, the less advantage of toxic and side effects, so obtain extensive use clinically.The preparation of now having used clinically has tablet, capsule, granule, oral liquid, eye drop, nasal drop, ointment, eye ointment and injection etc., also has mist agent launch abroad.This product injection is a small-volume injection, specification is 1ml:0.1g, but can quiet also intramuscular injection, during intravenous drip this product being added in 5% glucose injection or the normal saline dilution back uses, the a drug amount is 0.5-1g, be that 5-10 props up, the not only danger of making troubles and causing medicinal liquid to infect easily for clinical use.
Purpose of the present invention aims to provide a kind of heavy dose of ribavirin large infusion preparation that uses that is exclusively used in.
Mainly contain in per 100 ml of formulation of ribavirin large infusion series preparation of the present invention: sodium chloride 0.6-0.9g, glucose 4-10g, ribavirin 0.5-1g.
Mainly contain in per 100 ml of formulation of ribavirin large infusion series preparation of the present invention: sodium chloride 0.6-0.9g, ribavirin 0.5-1g.
Mainly contain in per 100 ml of formulation of ribavirin large infusion series preparation of the present invention: glucose 4-10g, ribavirin 0.5-1g.
Ribavirin large infusion series preparation of the present invention is according to clinical needs, satisfy clinical practice consumption 0.5-1g ribavirin dosage range, more easy to use than small-volume injection (1ml:0.1g * 5-10 prop up be added in 100ml normal saline or the glucose injection dilution posterior vein instil), simplify the operation, save the operating time.Avoid foreign body rejection, the ribavirin large infusion preparation is the patients venoclysis directly, has avoided extracting injection glucose or sodium chloride infusion solutions intermediate link by small-volume injection, thereby has stopped the cross infection in this medication process, improve medicine quality, ensure drug safety.Packing Unit is big, and one time use amount is also big, and suitable pH value and osmotic pressure are arranged, and does not allow thermal source and exists.And can be made into plurality of specifications, medical personnel can directly select for use according to patient's situation.
Embodiment:
Embodiment 1: the ribavirin sodium chloride injection
Prescription ribavirin 5g
Sodium chloride for injection 8g
Water for injection is added to 1000ml
Measure about 700-800ml water for injection, add the sodium chloride of recipe quantity, stirring and dissolving, add proper amount of active carbon and boiled 5-10 minute, filter carbon removal, add ribavirin 5g stir molten after, transfer PH4-6, add the injection water, add the carbon removal of proper amount of active carbon agitation and filtration to 1000ml, fine straining, fill is sealed in the 100ml infusion bottle, sterilization, check, packing promptly.Can be made into 100ml, the bottled preparation of 250ml.
Embodiment 2: the ribavirin glucose injection
Production technology changes sodium chloride among the embodiment 1 into 9% glucose with embodiment 1.
Embodiment 3: the ribavirin Dextrose and Sodium Chloride Inj.
Production technology will add 0.85% sodium chloride substantially with embodiment 1 among the embodiment 1.
Claims (3)
1, a kind of ribavirin large infusion series preparation is characterized in that mainly containing in per 100 ml of formulation: sodium chloride 0.6-0.9g, glucose 4-10g, ribavirin 0.5-1g.
2, a kind of ribavirin large infusion series preparation is characterized in that mainly containing in per 100 ml of formulation: sodium chloride 0.6-0.9g, ribavirin 0.5-1g.
3, a kind of ribavirin large infusion series preparation is characterized in that mainly containing in per 100 ml of formulation: glucose 4-10g, ribavirin 0.5-1g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97102748A CN1194831A (en) | 1997-04-01 | 1997-04-01 | Ribavirin large infusion series preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97102748A CN1194831A (en) | 1997-04-01 | 1997-04-01 | Ribavirin large infusion series preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1194831A true CN1194831A (en) | 1998-10-07 |
Family
ID=5166413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97102748A Pending CN1194831A (en) | 1997-04-01 | 1997-04-01 | Ribavirin large infusion series preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1194831A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101884612A (en) * | 2010-06-29 | 2010-11-17 | 上海华中药业有限公司 | Preparation method of large volume ribavirin injection |
| CN102366401A (en) * | 2011-09-28 | 2012-03-07 | 河南辅仁怀庆堂制药有限公司 | Ribavirin injection and preparation process thereof |
| CN103635196A (en) * | 2011-03-02 | 2014-03-12 | J·深塔格 | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection |
| CN105363035A (en) * | 2011-10-21 | 2016-03-02 | 艾伯维公司 | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
-
1997
- 1997-04-01 CN CN97102748A patent/CN1194831A/en active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9730951B2 (en) | 2010-03-03 | 2017-08-15 | Volant Holdings Gmbh | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a Hepatitis C virus infection |
| US10245277B2 (en) | 2010-03-03 | 2019-04-02 | Volant Holdings Gmbh | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis C virus infection |
| CN101884612A (en) * | 2010-06-29 | 2010-11-17 | 上海华中药业有限公司 | Preparation method of large volume ribavirin injection |
| CN103635196A (en) * | 2011-03-02 | 2014-03-12 | J·深塔格 | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection |
| JP2014506928A (en) * | 2011-03-02 | 2014-03-20 | ジェローム シェンターク， | Composition, therapeutic method and diagnostic method for the treatment of hepatic steatosis alone or with hepatitis C virus infection |
| EP2680859A4 (en) * | 2011-03-02 | 2014-12-17 | Jerome Schentag | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection |
| US9370528B2 (en) | 2011-03-02 | 2016-06-21 | Volant Holdings Gmbh | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis C virus infection |
| CN110152000A (en) * | 2011-03-02 | 2019-08-23 | J·深塔格 | For fatty degeneration of liver or treatment to be used individually with the adipohepatic composition of infection with hepatitis C virus |
| CN102366401A (en) * | 2011-09-28 | 2012-03-07 | 河南辅仁怀庆堂制药有限公司 | Ribavirin injection and preparation process thereof |
| CN105363035A (en) * | 2011-10-21 | 2016-03-02 | 艾伯维公司 | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0059694B1 (en) | Drug administration device | |
| AU754537B2 (en) | Novel pharmaceutical composition for use in emergency treatment and preparation method thereof | |
| TW200301694A (en) | Bicarbonate-based solutions for dialysis therapies | |
| CN101011397A (en) | Pantoprazole sodium freeze dried injection and preparation method thereof | |
| CN1044559C (en) | "Ailing" anticancer injection | |
| CN102836171A (en) | Solution for surgery and endoscope washing and preparation method thereof | |
| CN1194831A (en) | Ribavirin large infusion series preparation | |
| CN101190214B (en) | Paclitaxel injection and preparation method thereof | |
| CN101450075B (en) | Hydroxyethyl starch 130/0.4 sodium chloride injection and preparation method and use thereof | |
| CN102293741B (en) | Bromhexine hydrochlorie injection, its preparation method and application | |
| CN103381140A (en) | Inosine-common salt composition and preparation method thereof | |
| CN104922060B (en) | A kind of Ibandronate composition | |
| CN1468600A (en) | Preparation method of doxofylline glucose injection | |
| CN101984975A (en) | Medical composition containing cordycepin derivatives | |
| CN100544734C (en) | Compound fructose electrolyte injection and preparation method thereof | |
| CN106806418A (en) | A kind of swap buffers Neulized inhalation pharmaceutical solutions and preparation method thereof | |
| CN101301304A (en) | Chinese medicinal composition for treating ischemic stroke and preparation thereof | |
| CN1346648A (en) | Diemailing injection and its preparing process | |
| CN1191730A (en) | Serial crigeron breviscapus preparations for infusion | |
| CN102366399A (en) | Procaine hydrochloride injection and its production technology | |
| CN100563664C (en) | A kind of liquid preparation and its production and use | |
| CN107789343A (en) | A kind of medicine for treating antimigraine and preparation method thereof | |
| CN108926703A (en) | Ossotide glucose injection | |
| CN102008461A (en) | Ibuprofen drug composite for injection | |
| CN107773581A (en) | A kind of silver yellow Neulized inhalation pharmaceutical solutions and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |